Catalyst Dossier · compiled by CeliA 🧫

Pacira BioSciences, Inc. (PCRX)

Pharmaceutical Preparations · market cap $879M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-04Earningsimp 5/10
2026-08-15 (est.)Phase 3 · ZILRETTAimp 9/10
2026-12-15 (est.)Phase 3 · ZILRETTAimp 9/10
2027-03-15 (est.)Phase 2 · Enekinragene Inzadenovec (PCRX-201)imp 7/10

Pipeline

Asset	Phase	Indication
SKY0402	Phase 3	Hemorrhoid
FX006	Phase 3	Osteoarthritis of the Knee
FX005	Phase 2	Osteoarthritis, Knee
Bupivacaine liposome	Phase 3	Dental Pain
EXPAREL 266 mg	Phase 3	Posterolateral Thoracotomy
SKY0402 + bupivacaine HCl	Phase 2	Postoperative Pain
Bupivacaine HCl	Phase 3	Postoperative Pain
FX006 16 mg	Phase 2	Osteoarthritis of the Knee
FX006 10 mg	Phase 2	Osteoarthritis of the Knee
FX006 32 mg	Phase 3	Osteoarthritis of the Shoulder
EXPAREL 67 mg	Phase 3	Postoperative Pain
ZILRETTA	Phase 3	Glenohumeral Osteoarthritis
Exparel	Phase 3	Postoperative Pain Management
Enekinragene Inzadenovec (PCRX-201)	Phase 2	Osteoarthritis (OA) of the Knee
Bupivacaine liposome injectable suspension 266 mg	Phase 3	Bunionectomy
bupivacaine liposome injectable suspension	Phase 3	Pain
TCA IR 40 mg	Phase 2	Osteoarthritis of the Knee
Bupivacaine Hydrochloride	Phase 3	Lower Extremity Surgery
TAcs 40 mg	Phase 2	Bilateral Knee Osteoarthritis
TCA IR 40	Phase 3	Osteoarthritis of the Knee

Price & technical context

3-month

+11.4%

6-month

-2.6%

12-month

+9.3%

52-wk range

$19.16–$27.22

vs 50-day MA

+7.1%

vs 200-day MA

+8.6%

Realized vol

39.2%

Max drawdown

-59.7%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PCRX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.